166 filings
Page 2 of 9
8-K
ed6 cvk980abqtz8frfp
12 Oct 23
Material Modifications to Rights of Security Holders
4:01pm
8-K
kso22c yp9aq44ap4
18 Sep 23
Departure of Directors or Certain Officers
5:03pm
8-K
dvu zfzv6r6eb3th
11 Aug 23
T2 Biosystems Announces Second Quarter 2023 Financial Results
4:00pm
8-K
l7sn1gtpe0s10u7eqm3
9 Aug 23
Regulation FD Disclosure
4:10pm
8-K
xp4ex263hk7fuumbq
31 Jul 23
T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirements
9:11am
8-K
5u9d3xq 63bn9i
20 Jul 23
T2 Biosystems Receives FDA Breakthrough Device Designation for Candida Auris Diagnostic Test
8:30am
8-K
fnh88 xt0
12 Jul 23
T2 Biosystems Announces Preliminary Second Quarter 2023 Financial Results
8:05am
8-K
0qmpyzyn jf0nnfai
6 Jul 23
Entry into a Material Definitive Agreement
8:08am
8-K
mzlc0brav 65lq9l
23 Jun 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:01pm
8-K
i934amnxd91trdt
9 Jun 23
Regulation FD Disclosure
8:45am
8-K
xzxl9go1dk829
5 Jun 23
T2 Biosystems Announces Submission for FDA Breakthrough Device Designation for Candida Auris Diagnostic Test
9:00am
8-K
skehezwqp9 5s8vt
30 May 23
T2 Biosystems Announces Second Largest Sepsis-Driven Instrument Sale in Company History
9:01am
8-K
t3eifhmq0mg6bdm5pmu6
25 May 23
T2 Biosystems Announces First Quarter 2023 Financial Results
4:55pm
8-K
c8662oe sxfz4
23 May 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:13pm
8-K
m9lhs0mf5 fqz
31 Mar 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:00pm
8-K
vhlibj0etm24cp
16 Mar 23
T2 Biosystems Announces Fourth Quarter and Full Year 2022 Financial Results
4:01pm
8-K
jf25sxs4896y
16 Feb 23
Other Events
4:17pm
8-K
biokja03 kk6aupnx21p
13 Feb 23
Other Events
4:05pm
8-K
c4ju04 7z
23 Jan 23
T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results
5:11pm
8-K
54v71zg4ookiyi07
25 Nov 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:01pm